Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 47 (8), 844-7

A Double Blind Trial of Sulpiride in Huntington's Disease and Tardive Dyskinesia

Clinical Trial

A Double Blind Trial of Sulpiride in Huntington's Disease and Tardive Dyskinesia

N Quinn et al. J Neurol Neurosurg Psychiatry.

Abstract

Eleven patients with Huntington's disease and nine patients with tardive dyskinesia participated in a randomised double-blind crossover trial of sulpiride (as sole antidopaminergic therapy) versus placebo. Although functional improvement was not seen in Huntington's disease patients, sulpiride reduced movement count and total dyskinesia score in both conditions. Sulpiride differs pharmacologically in several respects from conventional neuroleptics, and has not been convincingly shown to cause tardive dyskinesia. Among currently available treatments, it may therefore be considered a drug of choice for treatment of tardive dyskinesia.

Similar articles

See all similar articles

Cited by 18 PubMed Central articles

See all "Cited by" articles

References

    1. Br Med J. 1978 Jan 14;1(6105):77-8 - PubMed
    1. Nature. 1979 Jan 11;277(5692):93-6 - PubMed
    1. Neurology. 1979 Jan;29(1):1-3 - PubMed
    1. Psychopharmacology (Berl). 1979;66(1):73-7 - PubMed
    1. Arch Neurol. 1982 Aug;39(8):494-6 - PubMed

Publication types

Feedback